Wall Street analysts forecast that Odonate Therapeutics Inc (NASDAQ:ODT) will report ($1.10) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Odonate Therapeutics’ earnings. Odonate Therapeutics posted earnings of ($0.81) per share in the same quarter last year, which would suggest a negative year over year growth rate of 35.8%. The business is scheduled to announce its next quarterly earnings results on Wednesday, February 13th.
According to Zacks, analysts expect that Odonate Therapeutics will report full-year earnings of ($3.49) per share for the current financial year, with EPS estimates ranging from ($3.57) to ($3.41). For the next fiscal year, analysts anticipate that the firm will post earnings of ($3.63) per share, with EPS estimates ranging from ($3.96) to ($3.30). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Odonate Therapeutics.
Odonate Therapeutics (NASDAQ:ODT) last released its earnings results on Tuesday, October 23rd. The company reported ($0.98) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.02).
Separately, Zacks Investment Research upgraded Odonate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $31.00.
In other Odonate Therapeutics news, CEO Kevin C. Tang acquired 39,765 shares of the stock in a transaction dated Thursday, October 25th. The shares were acquired at an average cost of $15.35 per share, for a total transaction of $610,392.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin C. Tang acquired 40,000 shares of the stock in a transaction dated Wednesday, September 26th. The stock was acquired at an average price of $19.75 per share, for a total transaction of $790,000.00. The disclosure for this purchase can be found here. Insiders have purchased 273,761 shares of company stock worth $4,882,129 over the last quarter. 49.00% of the stock is owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. Tang Capital Management LLC lifted its position in shares of Odonate Therapeutics by 11.2% in the third quarter. Tang Capital Management LLC now owns 13,796,747 shares of the company’s stock valued at $267,795,000 after acquiring an additional 1,384,409 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Odonate Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 1,160,742 shares of the company’s stock worth $22,530,000 after purchasing an additional 86,394 shares during the last quarter. Redmile Group LLC increased its holdings in shares of Odonate Therapeutics by 2.8% in the second quarter. Redmile Group LLC now owns 610,600 shares of the company’s stock worth $13,482,000 after purchasing an additional 16,400 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Odonate Therapeutics by 1.4% in the third quarter. BlackRock Inc. now owns 338,825 shares of the company’s stock worth $6,576,000 after purchasing an additional 4,566 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Odonate Therapeutics by 18.5% in the third quarter. Vanguard Group Inc. now owns 316,733 shares of the company’s stock worth $6,148,000 after purchasing an additional 49,528 shares during the last quarter. Institutional investors and hedge funds own 92.23% of the company’s stock.
NASDAQ ODT opened at $15.00 on Monday. The firm has a market cap of $390.61 million and a P/E ratio of -6.49. Odonate Therapeutics has a fifty-two week low of $14.06 and a fifty-two week high of $32.00.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Further Reading: What does the Dow Jones Industrial Average (DJIA) measure?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.